H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50

H.C. Wainwright reiterated its Buy rating and $8.50 price target for Personalis (PSNL) following positive clinical data from the Phase 3 NeoADAURA study, conducted with AstraZeneca, which validated Personalis' NeXT Personal assay as a prognostic indicator for lung cancer treatment efficacy. While the company reported a Q2'25 revenue miss at $17.2 million against a $20.07 million forecast, it surpassed EPS estimates and maintains strong liquidity with a 6.09 current ratio. This clinical validation underscores the potential of Personalis' technology despite recent mixed financial performance, contributing to its over 26% stock surge in the past six months.

Analysis

Personalis (PSNL) has received significant validation for its NeXT Personal molecular residual disease (MRD) assay following the release of positive data from the Phase 3 NeoADAURA study, conducted in partnership with AstraZeneca. The results demonstrate the assay's utility as a prognostic indicator for the efficacy of osimertinib therapy in patients with resectable EGFR-mutated non-small cell lung cancer, a key clinical milestone. This positive development prompted H.C. Wainwright to reiterate its Buy rating and an $8.50 price target, implying substantial upside from its current trading price of $5.24. While the clinical news is a strong tailwind, the company's recent financial performance presents a mixed picture. For Q2 2025, Personalis reported an EPS of -$0.23, narrowly beating the -$0.24 forecast, but revenue of $17.2 million missed expectations by 14.3%. Mitigating concerns over this revenue shortfall is the company's robust balance sheet, which features more cash than debt and a strong current ratio of 6.09, providing financial flexibility. The stock's 26% surge over the past six months indicates that the market is increasingly focused on the long-term potential of its MRD technology rather than near-term revenue figures.

Key Decisions for Investors

• Investors should weigh the significant long-term potential demonstrated by the positive NeoADAURA clinical data and strong analyst price target against the near-term headwind of the recent 14.3% revenue miss.
• Consider the company's strong liquidity, evidenced by a 6.09 current ratio and a cash position exceeding debt, which provides a crucial buffer to navigate revenue shortfalls while advancing its technology.
• Monitor for future milestones related to the commercial adoption and revenue generation from the NeXT Personal assay, as this will be the key catalyst to justify further appreciation beyond the stock's recent 26% gain.